Double-blinded randomized controlled trials (RCTs) have contributed much important evidence to guide treatment decisions in neurology. RCTs are relatively straightforward to conduct, provided that they investigate common diseases, have clearly defined outcome measures, and are of short duration. In neurology, however, many diseases are uncommon, have no consensus outcome measures, and develop over decades. Basic research into neurological diseases continues to identify candidate therapies faster than they can be tested for their clinical utility, leading to a 'translational gap'. Futility trials were initially developed in oncology to efficiently test candidate therapies in phase II trials. As single-arm unblinded studies, futility trials are relatively easy to conduct, and they generally require smaller sample sizes than RCTs. In this article, we discuss futility models, highlighting their advantages as well as challenges to their application in several neurological diseases, including Parkinson disease, stroke and multiple sclerosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrneurol.2015.34 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications.
JTO Clin Res Rep
December 2024
Department of Pulmonary Diseases, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands.
This review discusses the current data on predictive and prognostic biomarkers in oligometastatic NSCLC and discusses whether biomarkers identified in other stages and widespread metastatic disease can be extrapolated to the oligometastatic disease (OMD) setting. Research is underway to explore the prognostic and predictive value of biological attributes of tumor tissue, circulating cells, the tumor microenvironment, and imaging findings as biomarkers of oligometastatic NSCLC. Biomarkers that help define true OMD and predict outcomes are needed for patient selection for oligometastatic treatment, and to avoid futile treatments in patients that will not benefit from locoregional treatment.
View Article and Find Full Text PDFA 'good death' needs good cooperation with health care professionals - a qualitative focus group study with seniors, physicians and nurses in Germany.
BMC Palliat Care
December 2024
Department of General Practice, University Medical Center Göttingen, Humboldtallee 38, Göttingen, 37073, Germany.
Background: Studies investigating notions of a 'good death' tend to focus on specific medical conditions and specific groups of people. Therefore, their results are often poorly comparable, making it difficult to anticipate potential points of conflict in practice. Consequently, the study explores how to achieve a good death from the perspective and experience of physicians, nursing staff, and seniors.
View Article and Find Full Text PDFA randomized phase 2 study of efmarodocokin alfa, an IL-22 agonist, versus vedolizumab in patients with ulcerative colitis.
Clin Gastroenterol Hepatol
December 2024
Christian-Albrecht University of Kiel, Kiel, Germany.
Background And Aims: Efmarodocokin alfa is an interleukin (IL)-22 agonist, with favorable pharmacokinetic (PK) properties and an acceptable safety profile. This study further explored the therapeutic potential of efmarodocokin alfa compared to vedolizumab in patients with ulcerative colitis (UC).
Methods: This randomized phase 2 trial evaluated the efficacy, safety, PK, and pharmacodynamics of 3 doses of efmarodocokin alfa administered intravenously every 4 weeks (30 μg/kg [n=43], 60 μg/kg [n=44], and 90 μg/kg [n=43]) compared with placebo (n=22) and with vedolizumab (n=43) in the treatment of moderate to severe UC.
Quality-of-Life Analysis of a Phase II Randomised Controlled Trial Comparing Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy in Locally Advanced Rectal Cancer.
Clin Oncol (R Coll Radiol)
November 2024
St Luke's Radiation Oncology Network, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland.
Article Synopsis
- Neoadjuvant radiotherapy is crucial for treating locally advanced rectal cancer, and this study compares the quality-of-life outcomes between two techniques: three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT).
- A phase II randomized trial involved 94 patients who received chemoradiotherapy and were assigned to either 3DCRT or IMRT; their quality of life was assessed using specific questionnaires throughout the treatment and at a six-month follow-up.
- Although the trial ended early due to the futility of its primary endpoint, the results indicated that while emotional functioning improved, other aspects of quality of life declined; notably, IMRT showed better physical and role functioning during the final week
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).
J Alzheimers Dis
December 2024
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Background: Gantenerumab is a fully human anti-amyloid-β (Aβ) immunoglobulin G1 monoclonal antibody for subcutaneous (SC) administration. The efficacy and safety of low-dose (105 mg or 225 mg) gantenerumab were investigated in SCarlet RoAD (SR; NCT01224106), a Phase III, double-blind (DB), placebo-controlled study in participants with prodromal Alzheimer's disease. Following a pre-planned futility analysis, SR was converted into an open-label extension (OLE) study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!